{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT03151967: Phase 2/Phase 3 Interventional Completed Urinary Tract Infections (UTI's)
(2015)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04431934: Not Applicable Interventional Unknown status CARRIER STATE
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04431934: Not Applicable Interventional Unknown status CARRIER STATE
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02503202: Phase 3 Interventional Completed Prevention of Ebola Infection
(2015)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:itezocabtagene autoleucel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03562637: Phase 3 Interventional Recruiting Triple Negative Breast Cancer
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03430011: Phase 1/Phase 2 Interventional Completed Multiple Myeloma
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00006106: Phase 1 Interventional Withdrawn Lip and Oral Cavity Cancer
(1999)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:botaretigene sparoparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03554109: Phase 2 Interventional Withdrawn Triple Negative Breast Cancer (TNBC)
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE